使用帕利珠单抗预防呼吸道合胞病毒的成本效益。
Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
作者信息
Reeve Carole A, Whitehall John S, Buettner Petra G, Norton Robert, Reeve David M, Francis Fleur
机构信息
Department of Neonatology, The Townsville Hospital, Townsville, Queensland, Australia.
出版信息
J Paediatr Child Health. 2006 May;42(5):253-8. doi: 10.1111/j.1440-1754.2006.00850.x.
BACKGROUND
A monoclonal antibody, palivizumab, directed against respiratory syncytial virus (RSV) has been shown to decrease hospitalisation rates. Because of its expense, the cost-effectiveness of this agent should be determined for high-risk groups.
AIM
To determine characteristics of RSV infection in Townsville and the economic feasibility of palivizumab immunoprophylaxis in high-risk groups.
METHODS
Cases of RSV-positive bronchiolitis were retrospectively identified. Cases were grouped according to recognised risk factors. The hypothetical costs of palivizumab immunoprophylaxis for infants at risk were calculated.
RESULTS
The rate of hospitalisation with RSV-positive lower respiratory tract infection was 22 per 1000 live births but increased to 50 per 1000 among Indigenous babies born weighing <2500 g. The cost of preventing an admission in each of the identified high-risk groups, based on drug costs alone, ranged from AD 69,861 to AD 88,547.
CONCLUSION
Palivizumab was not cost-effective in the prophylaxis of RSV in the high-risk group of infants tested here.
背景
一种针对呼吸道合胞病毒（RSV）的单克隆抗体——帕利珠单抗，已被证明可降低住院率。由于其费用高昂，应确定该药物在高危人群中的成本效益。
目的
确定汤斯维尔市呼吸道合胞病毒感染的特征以及帕利珠单抗免疫预防在高危人群中的经济可行性。
方法
对呼吸道合胞病毒阳性细支气管炎病例进行回顾性识别。根据公认的危险因素对病例进行分组。计算了有风险婴儿使用帕利珠单抗免疫预防的假设成本。
结果
呼吸道合胞病毒阳性下呼吸道感染的住院率为每1000例活产22例，但出生体重<2500g的原住民婴儿中这一比例增至每1000例50例。仅基于药物成本，在每个已确定的高危人群中预防一次住院的成本在69861澳元至88547澳元之间。
结论
在此测试的高危婴儿群体中，帕利珠单抗预防呼吸道合胞病毒感染不具有成本效益。
Zotero 插件